Skip to main content

Table 2 Comparison based on the biochemical diagnosis

From: Scintigraphy evaluation of hyperthyroidism and its correlation with clinical and biochemical profiles

Variables

Hyperthyroidism

Subclinical hyperthyroidism

P value

Number

90

88

n/a

Mean age (years)

41.0 + 13.5

45.1 + 15.6

0.060

Female (%)

73.3

75

0.467

Presenting symptoms

 Dysphagia and/or hoarseness (%)

2.2

5.7

0.213

 Neck swelling (%)

7.8

4.6

0.281

 Neck tenderness (%)

4.4

0.0

0.063

 Weight loss (%)

13.3

3.4

0.016

 Tremor (%)

11.1

3.4

0.044

 Palpitation (%)

14.4

2.3

0.003

 Fatigue (%)

8.9

2.3

0.054

 Anxiety (%)

3.3

3.4

0.648

 Insomnia (%)

2.2

0.0

0.254

 Headache (%)

3.3

2.3

0.511

 Nausea and/or vomiting (%)

1.1

1.1

0.746

 Eye manifestations (%)

14.4

12.5

0.437

 Heat intolerance (%)

2.2

2.3

0.681

Comorbidities

 Upper respiratory tract infection (%)

13.3

13.6

0.563

 Hypertension (%)

12.2

19.3

0.137

 Hyperlipidemia (%)

11.1

9.1

0.422

 Type II Diabetes (%)

14.4

26.1

0.039

 Type I diabetes (%)

2.2

1.1

0.508

 Anemia (%)

5.6

12.5

0.087

 Dermatitis (%)

15.6

14.8

0.525

 Ischemic heart disease (%)

0.0

2.3

0.243

 Stroke (%)

0.0

2.3

0.243

 Deep vein thrombosis and/or pulmonary embolism (%)

2.2

1.1

0.508

Medications

 Carbimazole usage prior to the thyroid scan (%)

20.5

30.7

0.071

 Carbimazole usage after the thyroid scan (%)

14.4

10.2

0.266

 Carbimazole usage during the thyroid scan (%)

35.6

17.1

0.004

 Propranolol (%)

41.1

22.7

0.007

 Amiodarone (%)

0.0

1.1

0.494

 Artificial eye tears (%)

6.7

4.6

0.388

Laboratory data

 TSH (milli-international units per liter)

0.019 + 0.04

0.083 + 0.10

< 0.001

 Free T4 (pmol/L)

28.7 + 9.9

14.5 + 2.4

< 0.001

 Free T3 (pmol/L)

15.0 + 10.7

5.2 + 1.2

< 0.001

 Antithyroid peroxidase antibody (IU/mL)

137.2 + 228.9

736.2 + 1495.5

0.309

 Antithyroglobulin antibody (IU/mL)

140.6 + 185.1

384.7 + 657.8

0.161

 Vitamin D (ng/mL)

23.4 + 10.4

22.4 + 9.0

0.289

 Erythrocyte sedimentation rate (ESR) (mm/hr)

34.5 + 24.3

34.4 + 24.7

0.995

 C-Reactive protein (CRP) (mg/L)

9.8 + 12.4

11.3 + 9.3

0.719

Thyroid ultrasound

 Enlarged thyroid gland (%)

25.0

31.1

0.605

 Heterogenous (%)

52.2

61.4

0.337

 Hypervascular (%)

38.9

31.8

0.392

 Bilateral lymph node enlargement (%)

22.2

33.0

0.404

 Unilateral lymph node enlargement (%)

2.2

1.1

 Multiple lymph node enlargement (%)

27.8

38.6

0.093

 Single lymph node enlargement (%)

10.0

15.9

Thyroid uptake and scan

 Heterogenous (%)

26.7

48.9

0.006

0.006

 Homogenous (%)

66.7

43.2

 Mean uptake (%)

17.6 + 9.5

13.2 + 3.8

0.373

 Graves’ disease (%)

40

13.6

0.002

 Thyroiditis (%)

8.9

27.3

 Normal (%)

2.2

5.7

 Autonomous nodule (%)

6.7

3.4

 Toxic multi-nodular goiter (%)

34.4

40.9

 Simple goiter (%)

4.4

4.5

 Nodular goiter with cold nodule (%)

0.0

2.2

 Cold nodule (%)

1.1

1.1

 Toxic multi-nodular goiter with a cold nodule (%)

1.1

1.1

 Marine-Lenhart syndrome (%)

2.2

0.0

 Normal scan while taking carbimazole (%)

17.8

11.4

0.159

  1. This Table shows a comparison based on the biochemical diagnosis between Hyperthyroidism and Subclinical hyperthyroidism patients. The means and standard deviations are used for quantitative variables like the age, thyroid uptake scan and laboratory parameter. Percentages are used to express all other qualitative data. An independent sample t-test is used to identify significant differences between variables, and p-values ≤0.05 are considered significant